The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review
Open accessAbstract
INTRODUCTION: Generalized anxiety disorder (GAD) is a common form of anxiety disorder. Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and benzodiazepines (BZs) are the most commonly prescribed medications for GAD, but little is known about the relative efficacy of these pharmacological treatments. Areas covered: This study provides a meta-analytic review of the efficacy of these medications in the treatment of adults with GAD. A comprehensive literature search yielded 54 articles reporting 56 unique studies with 12,655 participants treated with either pill placebo (6,191 participants), SSRIs (16 trials, 2,712 participants), SNRIs (17 trials, 2,603 participants), or BZs (23 trials, 1,149 participants). The overall combined effect size was modest to moderate (Hedges' g = 0.37, p < 0.0001). Effect sizes decreased significantly over time. SSRIs (Hedges' g = 0.33) and SNRIs (Hedges' g = 0.36) demonstrated significantly lower effect sizes than BZs (Hedges' g = 0.50). These findings were not due to differences in treatment length or publication year. Expert opinion: The results of this study suggest that the most common forms of pharmacotherapy for adult GAD are moderately effective, with BZs being the most effective drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, BDZs demonstrate efficacy for the treatment of GAD (Gomez, Barthel, & Hofmann, 2018) and are still and even increasingly prescribed (Agarwal & Landon, 2019;Bachhuber, Hennessy, Cunningham, & Starrels, 2016).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Gomez, Barthel, & Hofmann, 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,586
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
The file drawer problem and tolerance for null results.
Rosenthal, R. (1979) · Psychological Bulletin · doi:10.1037/0033-2909.86.3.638 · Cited by 9,068 · cited 1×
“To address the file drawer problem, a classic fail-safe N analysis was conducted [33,34].”
MethodMeta-Analytic Procedures for Social Research
Rosenthal, R. (1991) · doi:10.4135/9781412984997 · Cited by 4,635
A Fail-Safe N for Effect Size in Meta-Analysis
Orwin, R. G. (1983) · Journal of Educational Statistics · doi:10.2307/1164923 · Cited by 2,064 · cited 2×
“N test [33] indicated that 354 trials with an effect size of zerowould be needed to yield an overall trivial effect of treatment over”
MethodPlacebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
Maier, W., Buller, R., Philipp, M., & Heuser, I. (1988) · Journal of Affective Disorders · doi:10.1016/0165-0327(88)90072-9 · Cited by 1,044 · cited 7×
“Using the Trim and Fill method [35], we determined that 17 studieswould need to fall to the left of themean (i.e. have an effect size smaller than the mean) and 0 studies would need to fall to the right of the mean (i.e. have an effect size larger than TX: treatment; HARS: Hamilton Anxiety Rating Scale; BZ: benzodiaze…”
BackgroundInfluentialCarpenter, J. K., Andrews, L. A., Witcraft, S. M., Powers, M. B., Smits, J. A. J., & Hofmann, S. G. (2018) · Depression and Anxiety · doi:10.1002/da.22728 · Cited by 846 · cited 1×
“97) with low to moderate heterogeneity [44,45].”
Self-citationHiggins, J. (2011) · Medical Entomology and Zoology · Cited by 816
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
Adjusting for publication bias in the presence of heterogeneity
Terrin, N., Schmid, C. H., Lau, J., & Olkin, I. (2003) · Statistics in Medicine · doi:10.1002/sim.1461 · Cited by 809
Peters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R., & Rushton, L. (2007) · Statistics in Medicine · doi:10.1002/sim.2889 · Cited by 716
Efficacy of treatments for anxiety disorders: a meta-analysis
Bandelow, B., Reitt, M., Röver, C., Michaelis, S., Görlich, Y., & Wedekind, D. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000078 · Cited by 555
Cognitive Effects of Long-Term Benzodiazepine Use: A Meta-Analysis
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418010-00004 · Cited by 552
Cuijpers, P., Sijbrandij, M., Koole, S. L., Andersson, G., Beekman, A. T., & Reynolds, C. F. (2013) · World Psychiatry · doi:10.1002/wps.20038 · Cited by 540
Psychological treatment of generalized anxiety disorder: A meta-analysis
Cuijpers, P., Sijbrandij, M., Koole, S., Huibers, M., Berking, M., & Andersson, G. (2014) · Clinical Psychology Review · doi:10.1016/j.cpr.2014.01.002 · Cited by 527 · cited 1×
“97) with low to moderate heterogeneity [44,45].”
Newman, M. G., Llera, S. J., Erickson, T. M., Przeworski, A., & Castonguay, L. G. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185544 · Cited by 472
Antidepressants for the Treatment of Generalized Anxiety Disorder
Rickels, K. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820230054005 · Cited by 416
Neurochemistry in the pathophysiology of autism.
McDougle, C. J., Erickson, C. A., Stigler, K. A., & Posey, D. J. (2005) · PubMed · Cited by 408
Gould, R. A., Otto, M. W., Pollack, M. H., & Yap, L. (1997) · Behavior Therapy · doi:10.1016/s0005-7894(97)80048-2 · Cited by 352
The Pharmacologic Treatment of Anxiety Disorders: A Review of Progress
Ravindran, L. N., & Stein, M. B. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06218blu · Cited by 317
Pregabalin in Generalized Anxiety Disorder: A Placebo-Controlled Trial
Pande, A. C., Crockatt, J. G., Feltner, D. E., Janney, C. A., Smith, W. T., Weisler, R. H., Londborg, P. D., Bielski, R. J., ZIMBROFF, D. L., Davidson, J. R. T., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.3.533 · Cited by 315
Davidson, J. R. T., DuPont, R. L., Hedges, D., & Haskins, J. T. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0805 · Cited by 302
Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives.
Longo, L. P., & Johnson, B. (2000) · PubMed · Cited by 302
Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis
Baldwin, D. S., Woods, R., Lawson, R., & Taylor, D. M. (2011) · BMJ · doi:10.1136/bmj.d1199 · Cited by 301
Gelenberg, A. J., Lydiard, R. B., Rudolph, R. L., AGUIAR, L. M. V. B., Haskins, J. T., & Salinas, E. O. (2000) · JAMA · doi:10.1001/jama.283.23.3082 · Cited by 299
Hartford, J. T., Kornstein, S. G., Liebowitz, M. R., Pigott, T. A., Russell, J. D., Detke, M. J., Walker, D. J., Ball, S. G., Dunayevich, E., Dinkel, J., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32807fb1b2 · Cited by 288
Pregabalin for Treatment of Generalized Anxiety Disorder
Rickels, K., Pollack, M. H., Feltner, D. E., Lydiard, R. B., Zimbroff, D. L., Bielski, R. J., Tobias, K., Brock, J., Zornberg, G. L., & Pande, A. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.1022 · Cited by 286
Rickels, K., Pollack, M. H., Sheehan, D. V., & Haskins, J. T. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.968 · Cited by 254
Feltner, D., Crockatt, J. G., Dubovsky, S., Cohn, C., Shrivastava, R., Targum, S., Liu-Dumaw, M., Carter, C. M., & Pande, A. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084032.22282.ff · Cited by 253
Paroxetine in the Treatment of Generalized Anxiety Disorder
Pollack, M. H., Zaninelli, R., Goddard, A. W., McCafferty, J. P., Bellew, K. M., Burnham, D. B., & Iyengar, M. K. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0508 · Cited by 246
Pharmacologic treatment of anxiety disorders.
MAVISSAKALIAN, M. R. (1982) · PubMed · Cited by 243
Ceulemans, D., Hoppenbrouwers, M., Gelders, Y. G., & Reyntjens, A. J. M. (1985) · Pharmacopsychiatry · doi:10.1055/s-2007-1017385 · Cited by 226
Efficacy and Safety of Pregabalin in the Treatment of Generalized Anxiety Disorder
Montgomery, S., Tobias, K., Zornberg, G. L., Kasper, S. F., & Pande, A. C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0511 · Cited by 211
Paroxetine Treatment of Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study
Rickels, K., Zaninelli, R., McCafferty, J. P., Bellew, K. M., Iyengar, M. K., & Sheehan, D. V. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.749 · Cited by 201
Davidson, J. R. T., Bose, A., Korotzer, A. R., & Zheng, H. (2004) · Depression and Anxiety · doi:10.1002/da.10146 · Cited by 179
An effect-size analysis of pharmacologic treatments for generalized anxiety disorder
Hidalgo, R. B., Tupler, L. A., & Davidson, J. R. T. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107076996 · Cited by 179
Allgulander, C., Hackett, D., & Salinas, E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.15 · Cited by 175
Power, K., Simpson, R., Swanson, V., Wallace, L. A., Feistner, A. T. C., & Sharp, D. (1990) · Journal of Anxiety Disorders · doi:10.1016/0887-6185(90)90026-6 · Cited by 166
Offidani, E., Guidi, J., Tomba, E., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000353198 · Cited by 166
Pharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Möller, H., Volz, H., Reimann, I. W., & Stoll, K.-D. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00011 · Cited by 147
Rynn, M. A., Russell, J. D., Erickson, J., Detke, M. J., Ball, S. G., Dinkel, J., Rickels, K., & Raskin, J. (2007) · Depression and Anxiety · doi:10.1002/da.20271 · Cited by 144
Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
Efficacy of Sertraline in a 12-Week Trial for Generalized Anxiety Disorder
Allgulander, C., Dahl, A. A., Austin, C., Morris, P., Søgaard, J., Fayyad, R. S., Kutcher, S., & Clary, C. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1642 · Cited by 140
A Meta-analytic Review of the Efficacy of Drug Treatment in Generalized Anxiety Disorder
Mitte, K., Noack, P., Steil, R., & Hautzinger, M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000155821.74832.f9 · Cited by 137
Delgado, P. L., Brannan, S. K., Mallinckrodt, C. H., Trân, P. V., McNamara, R. K., Wang, F., Watkin, J. G., & Detke, M. J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0603 · Cited by 135
Pharmacotherapy of anxiety disorders: a critical review.
Koen, N., & Stein, D. J. (2011) · PubMed · Cited by 124
Goodman, W. K., Bose, A., & Wang, Q. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.11.011 · Cited by 117
Baldwin, D. S., Huusom, A. K. T., & Mæhlum, E. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.012799 · Cited by 114
Roest, A. M., de Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A., & Turner, E. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.15 · Cited by 101
Kasper, S. F., Herman, B. K., Nivoli, G., Ameringen, M. V., Petralia, A., Mandel, F. S., Baldinetti, F., & Bandelow, B. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32831d7980 · Cited by 98
Benzodiazepine, psychotropic medication, and dementia: A population‐based cohort study
Shash, D., Kurth, T., Bertrand, M., Dufouil, C., Barberger‐Gateau, P., Berr, C., Ritchie, K. A., Dartigues, J., Bégaud, B., Alpérovitch, A., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.10.006 · Cited by 94
Efficacy of Duloxetine for the Treatment of Generalized Anxiety Disorder
Koponen, H., Allgulander, C., Erikson, J., Dunayevich, E., Pritchett, Y., Detke, M. J., Ball, S. G., & Russell, J. M. (2007) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v09n0203 · Cited by 93
Pharmacological treatment for generalized anxiety disorder in adults: an update
Reinhold, J. A., & Rickels, K. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1059424 · Cited by 88
Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder
Enkelmann, R. (1991) · Psychopharmacology · doi:10.1007/bf02244440 · Cited by 84
Nicolini, H., Bakish, D., Dueñas, H., Spann, M., Erickson, J., Hallberg, C., Ball, S., Sagman, D., & Russell, J. M. (2008) · Psychological Medicine · doi:10.1017/s0033291708003401 · Cited by 79
Cutler, N. R., Sramek, J. J., Hesselink, J. M. K., Krol, A., Roeschen, J., Rickels, K., & Schweizer, E. E. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199312000-00009 · Cited by 77
Sertraline Treatment for Generalized Anxiety Disorder
Brawman‐Mintzer, O., Knapp, R. G., Rynn, M. A., Carter, R. E., & Rickels, K. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0603 · Cited by 72
Merideth, C., Cutler, A. J., She, F., & Eriksson, H. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32834d9f49 · Cited by 68
Rickels, K., DeMartinis, N. A., & Aufdembrinke, B. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200002000-00004 · Cited by 68
Agomelatine in Generalized Anxiety Disorder: An Active Comparator and Placebo-Controlled Study
Stein, D. J., Ahokas, A., Márquez, M. S., Höschl, C., Oh, K. S., Jarema, M., Avedisova, A. S., Albarran, C., & Olivier, V. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08433 · Cited by 67
Gepirone and Diazepam in Generalized Anxiety Disorder
Rickels, K., Schweizer, E. E., DeMartinis, N. A., Mandos, L. A., & Mercer, C. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00006 · Cited by 64
Steiner, M. S., Allgulander, C., Ravindran, A. V., Kosar, H., Burt, T., & Austin, C. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.648 · Cited by 59
Lenox‐Smith, A., & Reynolds, A. (2003) · Europe PMC (PubMed Central) · Cited by 58
Sugarman, M. A., Loree, A. M., Baltes, B. B., Grekin, E. R., & Kirsch, I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106337 · Cited by 55
Bose, A., Korotzer, A. R., Gommoll, C., & Li, D. (2007) · Depression and Anxiety · doi:10.1002/da.20355 · Cited by 53
Frampton, J. E., & Foster, R. H. (2006) · CNS Drugs · doi:10.2165/00023210-200620080-00010 · Cited by 53
Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Simon, J. S. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12328 · Cited by 50
de Vries, Y. A., de Jonge, P., van den Heuvel, E., Turner, E. H., & Roest, A. M. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.173450 · Cited by 50
Alaka, K., Noble, W. C., Montejo, A. L., Dueñas, H., Munshi, A., Strawn, J. R., Lenox‐Smith, A., AHL, J. S. B., Bidzan, L., Dorn, B., et al. (2014) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4088 · Cited by 48
Nimatoudis, I., Zissis, N. P., Kogeorgos, J., Theodoropoulou, S., Vidalis, A. A., & KAPRINIS, G. S. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200411000-00003 · Cited by 47
Hackett, D., Haudiquet, V., & Salinas, E. O. (2003) · European Psychiatry · doi:10.1016/s0924-9338(03)00046-4 · Cited by 47
Allgulander, C., Hartford, J. T., Russell, J. D., Ball, S. G., Erickson, J., Raskin, J., & Rynn, M. A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182202 · Cited by 47
Gommoll, C., Durgam, S., Mathews, M., Forero, G., Núñez, R., Tang, X., & Thase, M. E. (2015) · Depression and Anxiety · doi:10.1002/da.22365 · Cited by 44
Cohn, J. B., Rickels, K., & Steege, J. F. (1989) · Current Medical Research and Opinion · doi:10.1185/03007998909115213 · Cited by 40
Baldwin, D. S., Hou, R. H., Gordon, R., Huneke, N. T. M., & Garner, M. J. (2017) · CNS Drugs · doi:10.1007/s40263-017-0423-2 · Cited by 40
Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China.
Wu, W., Wang, G., Ball, S. G., Desaiah, D., & Ang, Q.-Q. (2011) · PubMed · Cited by 39
Ansseau, M., Olié, J., von Frenckell, R., Jourdain, G., Stehlé, B., & Guillet, P. (1991) · Psychopharmacology · doi:10.1007/bf02245646 · Cited by 37
McLeod, D. R., Hoehn‐Saric, R., Porges, S. W., & Zimmerli, W. D. (1992) · Psychopharmacology · doi:10.1007/bf02245268 · Cited by 35
Boyer, W. F., & Feighner, J. P. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300830-00006 · Cited by 34
Chan, T., Leung, W. C. Y., Li, V., Wong, K. W., Chu, W.-M., Leung, K. C., Ng, Y.-Z., Kai, Y. G., Shea, Y. F., Chang, S. R., et al. (2017) · Psychogeriatrics · doi:10.1111/psyg.12239 · Cited by 31
Fontaine, R., Mercier, P., Beaudry, P., Annable, L., & Chouinard, G. (1986) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1986.tb06268.x · Cited by 30
Vilazodone in patients with generalized anxiety disorder
Gommoll, C., Forero, G., Mathews, M., Núñez, R., Tang, X., Durgam, S., & Sambunaris, A. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000096 · Cited by 27
Temporal profile of brain response to alprazolam in patients with generalized anxiety disorder
Brown, G. G., Ostrowitzki, S., Stein, M. B., von Kienlin, M., Liu, T. T., Simmons, A. N., Wierenga, C. E., Stein, O. Y., Bruns, A., Bischoff‐Grethe, A., et al. (2015) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2015.06.016 · Cited by 26
Efficacy and Safety of Lesopitron in Outpatients with Generalized Anxiety Disorder
Fresquet, A., Sust, M., Lloret, A., Murphy, M. F., Carter, F. J., Campbell, G. M., & Marion-Landais, G. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19041 · Cited by 26
Zareifopoulos, N., & Dylja, I. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.01.016 · Cited by 26
Duloxetine in the treatment of generalized anxiety disorder
Kornstein, S. G., Russell, J. M., Spann, M. E., Crits-Christoph, P. F., & Ball, S. G. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.9.2.155 · Cited by 25
Buoli, M., Dell’Osso, B. M., Bosi, M. F., & Altamura, C. A. (2010) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02136.x · Cited by 21
Pharmakotherapie bei Angsterkrankungen
Zwanzger, P. (2016) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0042-106764 · Cited by 21
Bromazepam in generalized anxiety
Kragh-Sørensen, P., Holm, P., Fynboe, C., Schaumburg, E., Andersen, B. N., Bech, P., & Pichard, J. (1990) · Psychopharmacology · doi:10.1007/bf02244611 · Cited by 20
Pourmotabbed, T., McLeod, D. R., Hoehn‐Saric, R., Hipsley, P. A., & Greenblatt, D. J. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199606000-00002 · Cited by 16
Li, X., Zhu, L., Su, Y., & Fang, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185865 · Cited by 16
Predictors of Pharmacotherapy Response in Generalized Anxiety Disorder: A Systematic Review
Ferreira-Garcia, R., Mochcovitch, M. D., do Cabo, M. C., Nardi, A. E., & Freire, R. C. R. (2017) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000127 · Cited by 14
Dobrea, C., Buoli, M., Arici, C., Camuri, G., Dell’Osso, B. M., & Altamura, A. C. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.720971 · Cited by 13
Fu, J., Peng, L., & Li, X. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s104050 · Cited by 12
Ferreira, L. S., Figueira, M. L., Bessa-Peixoto, A., Marieiro, A. N., Albuquerque, R., Paz, C., Cerqueira, A., Dami??o, P., Dolgner, A., & Dingemanse, J. (2003) · Clinical Drug Investigation · doi:10.2165/00044011-200323040-00003 · Cited by 11
Fontaine, R., Chouinard, G., & Annable, L. (1984) · PubMed · Cited by 10
Zhang, Y., Huang, G., Yang, S., Liang, W., Zhang, L., & Wang, C. (2015) · Asia-Pacific Psychiatry · doi:10.1111/appy.12203 · Cited by 10
A fixed-dose study of adinazolam-SR tablets in generalized anxiety disorder
Wilcox, C. S., Ryan, P. J., Morrissey, J. L., Cohn, J. B., Defrancisco, D. F., Rd, L., & Heiser, J. F. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90124-4 · Cited by 7
Benzodiazepines risk, abuse, and dependence: a tsunami in a tea cup.
Hidalgo, R. B., & Sheehan, D. V. (2009) · PubMed · Cited by 4
Research works printed but not linked: 8
- Longo LP, 2000, Am Fam Physician, 61, 2121
- Hidalgo RB, 2010, Psychiatry (Edgmont), 6, 13
- Stewart SA, 2005, J Clin Psychiatry, 66, 9
- Borenstein M, 1999, Comprehensive meta-analysis: A computer program for research
- Fontaine R, 1984, Psychopharmacology Bulletin, 20, 126
- Koponen H, 2007, J Clin Psychiatry, 9, 100
- Lenox-Smith A, 2003, Br J Gen Pract, 53, 772
- Wu WY, 2011, Chin Med J (Engl), 124, 3260
Cited by
Sorted by citations
Penninx, B. W., Pine, D. S., Holmes, E. A., & Reif, A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00359-7 · Cited by 740
Szuhany, K. L., & Simon, N. M. (2022) · JAMA · doi:10.1001/jama.2022.22744 · Cited by 541
Leichsenring, F., Steinert, C., Rabung, S., & Ioannidis, J. P. A. (2022) · World Psychiatry · doi:10.1002/wps.20941 · Cited by 485
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
The prefrontal cortex, pathological anxiety, and anxiety disorders
Kenwood, M. M., Kalin, N. H., & Barbas, H. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01109-z · Cited by 379
Metadata
- Authors
- Gomez, A. F., Barthel, A. L., & Hofmann, S. G.
- Affiliations
- Department of Psychological and Brain Sciences, Boston University, Boston, MA, USA
- Boston University (US)
- Corresponding author
- Hofmann, Stefan G.
- ORCID
- Hofmann, Stefan G.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2018-05-24
- Volume
- 19
- Issue
- 8
- Pages
- 883-894
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- PMC
- PMC6097846
- OpenAlex
- W2804266260
- Cited by
- 125
- References
- 102
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 32 · 2023: 18 · 2022: 11 · 2021: 16 · 2020: 17 · 2019: 9 · 2018: 2
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R34MH099311)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- generalized anxiety disorder, benzodiazepines, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, pharmacotherapy efficacy, antidepressant comparison, placebo response, adults
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Anxiety Disorders, Benzodiazepines, Humans, Anti-Anxiety Agents, Databases, Factual, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
